Email Us
Call Us
AUSTIN, Texas – December 20, 2013 – Altogen Labs today detailed the orthotopic and metastatic configurations available across its lung cancer model collection, extending beyond subcutaneous efficacy testing into the biology that determines clinical outcome.
Lung cancer mortality is driven by metastatic spread, and by the failure of compounds effective in vitro to perform in vivo. The Altogen Labs metastatic lung cancer models introduces tumor cells orthotopically into the lungs or by tail vein injection, enabling evaluation of spread to liver, bone, and brain. The Altogen collection covers the molecular subtypes driving current development: HCC827 and NCI-H1975 for EGFR-mutant disease including T790M resistance; H1993 for MET-amplified tumors; Calu-3, Calu-6, H460, H1155, H1703, and NCI-H226 across non-small cell histologies; DMS273 and NCI-H526/H522 for small cell lung cancer; and the LL2 allograft model for immunocompetent work.
Orthotopic and metastatic lung cancer models provide experimental advantages when tumor–microenvironment interactions, tissue-specific growth, vascular dissemination, or secondary organ colonization are central to the study objective. Implantation within the pulmonary compartment exposes tumor cells to lung-specific stromal, vascular, and extracellular matrix conditions that are not reproduced by subcutaneous flank models. Metastatic configurations can be used to characterize dissemination patterns, organ-specific tumor burden, and treatment effects on both primary and secondary lesions, with endpoints incorporating bioluminescence imaging, gross pathology, histopathology, immunohistochemistry, and molecular analysis of collected tissues.
Model selection can also be aligned with the molecular mechanism of the investigational agent. EGFR-mutant models are relevant to studies of receptor tyrosine kinase inhibition and acquired resistance, while MET-amplified and other genetically defined NSCLC models support evaluation of pathway-specific therapeutics and rational combination strategies. Study designs may incorporate pharmacodynamic analysis of signaling pathways such as EGFR–RAS–RAF–MEK–ERK and PI3K–AKT–mTOR, together with assessment of proliferation, apoptosis, angiogenesis, epithelial–mesenchymal transition, and metastatic progression. These molecular and pathological endpoints can be integrated with tumor growth, survival, PK/PD, and organ-specific metastasis measurements to provide a more comprehensive assessment of therapeutic activity.
Altogen Labs has published technical documentation for the A549 model describing established tumor growth kinetics, orthotopic and metastatic study design, dosing options, tissue collection, and analytical endpoints, giving sponsors full visibility into study conduct before commitment.
Patient-derived xenografts for lung cancer are available within the company’s PDX model collection, alongside patient-derived cell cultures and organoids for matched in vitro work.
About Altogen Labs
Altogen Labs is a preclinical CRO supporting drug development programs across oncology, pharmacology, toxicology, and translational research. The company has extensive experience with xenograft tumor models for preclinical efficacy studies and in vivo toxicology for safety evaluation, with a strong emphasis on high-quality, reproducible study execution and full client ownership of project-specific intellectual property. Altogen Labs works with pharmaceutical, biotechnology, and academic organizations worldwide to evaluate therapeutic candidates in validated in vivo models and generate data for efficacy, safety, PK/PD, pathology, and IND-supporting studies. The company provides integrated preclinical services from early-stage evaluation through advanced development.
Contact Information:
Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com